T3D Therapeutics, a Research Triangle Park, NC-based clinical stage drug development company, closed on a $15m financing.
A cornerstone investor provided the funds along with support from the National Institute on Aging (NIA), part of NIH.
The company intends to use the funds to begin the PIONEER Study of T3D-959, a novel, metabolic-focused AD drug treatment.
Led by Chief Executive Officer John Didsbury, Ph.D., and Chief Medical Officer Warren Strittmatter, M.D., T3D Therapeutics is a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD).
T3D-959 is a small molecule, orally-delivered, brain-penetrating dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.
The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer’s Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) is expected to initiate patient dosing in early 2020. It is a double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 256 adults with mild-to-moderate Alzheimer’s disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of three different doses of T3D-959 or a placebo for 24 weeks. PIONEER is projected to start enrolling subjects in the first quarter of 2020.
FinSMEs
04/11/2019